Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(19):1420-1424; doi:10.1093/jnci/djj378
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Henshall, S. M.
Right arrow Articles by Sutherland, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henshall, S. M.
Right arrow Articles by Sutherland, R. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

BRIEF COMMUNICATION

Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy

Susan M. Henshall, Lisa G. Horvath, David I. Quinn, Sarah A. Eggleton, John J. Grygiel, Phillip D. Stricker, Andrew V. Biankin, James G. Kench, Robert L. Sutherland

Affiliations of authors: Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, Sydney, Australia (SMH, LGH, SAE, AVB, JGK, RLS); Department of Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia (LGH); Department of Tissue Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia (JGK); Division of Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA (DIQ); Department of Urology (PDS) and Department of Medical Oncology (JJG), St Vincent's Hospital, Darlinghurst, Sydney, Australia; Division of Surgery, Bankstown Hospital, Bankstown, NSW, Australia (AVB)

Correspondence to: Susan M. Henshall, PhD, Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, NSW 2010, Australia (e-mail: s.henshall{at}garvan.org.au).

The risk of metastatic progression for prostate cancer patients who undergo radical prostatectomy is best estimated presently based on prostate-specific antigen (PSA) doubling time (PSADT). However, additional markers of risk are needed to identify patients who may benefit from aggressive salvage treatment. A decrease in zinc-alpha2-glycoprotein (AZGP1) mRNA levels in malignant prostate epithelium was previously shown to predict biochemical recurrence, as defined by rising levels of serum PSA after radical prostatectomy. We assessed the reliability with which AZPG1 expression could predict clinical recurrence and metastatic progression. Using immunohistochemical methods, we analyzed AZPG1 expression in malignant prostate epithelium in prostatectomy specimens from 228 prostate cancer patients. Low (i.e., absent or weak) AZGP1 expression was associated with clinical recurrence (defined as confirmed localized recurrence, metastasis, or death from prostate cancer; hazard ratio [HR] = 4.8, 95% confidence interval [CI] = 2.2 to 10.7, P<.001) and with bony metastases or death from prostate cancer (HR = 8.0, 95% CI = 2.6 to 24.3, P<.001). Among the 17 patients in the cohort in whom clinical recurrence was associated with short PSADT, absent or weak AZGP1 expression was observed in 13 patients. If these preliminary findings are validated in independent cohorts, the measurement of AZGP1 levels in radical prostatectomy specimens may permit an accurate and timely assessment of risk of metastatic progression after radical prostatectomy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. E.S. Comstock, M. A. Augello, R. P. Benito, J. Karch, T. H. Tran, F. E. Utama, E. A. Tindall, Y. Wang, C. J. Burd, E. M. Groh, et al.
Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
Clin. Cancer Res., September 1, 2009; 15(17): 5338 - 5349.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Vanni, A. Kazeros, R. Wang, B.-G. Harvey, B. Ferris, B. P. De, B. J. Carolan, R.-H. Hubner, T. P. O'Connor, and R. G. Crystal
Cigarette Smoking Induces Overexpression of a Fat-Depleting Gene AZGP1 in the Human
Chest, May 1, 2009; 135(5): 1197 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. L. Blum, T. Koyama, A. E. M'Koma, J. M. Iturregui, M. Martinez-Ferrer, C. Uwamariya, J. A. Smith Jr., P. E. Clark, and N. A. Bhowmick
Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy
Clin. Cancer Res., December 1, 2008; 14(23): 7790 - 7797.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Md. I. Hassan, A. Waheed, S. Yadav, T. P. Singh, and F. Ahmad
Zinc {alpha}2-Glycoprotein: A Multidisciplinary Protein
Mol. Cancer Res., June 1, 2008; 6(6): 892 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Lapointe, C. Li, C. P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J. D. Brooks, and J. R. Pollack
Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis
Cancer Res., September 15, 2007; 67(18): 8504 - 8510.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.